Browse > Article
http://dx.doi.org/10.5352/JLS.2014.24.2.173

Fulvestrant Does Not Have Antagonistic Effect on 17β-estradiol's Anti-proliferative Action in Cultured Chinese Hamster Ovarian Cell Line  

Kim, Hyun Hee (Department of Pharmaceutical Engineering, College of Bioscience, Gyeongnam National University of Science & Technology)
Park, Hyeong Cheol (Division of Applied Life Science (Brain Korea 21 Program) and Plant Molecular Biology and Biotechnology Research Center, Gyeongsang National University)
Min, Gyesik (Department of Nursing, College of Bioscience, Gyeongnam National University of Science & Technology)
Publication Information
Journal of Life Science / v.24, no.2, 2014 , pp. 173-180 More about this Journal
Abstract
Estrogen can promote or inhibit cellular proliferation depending on tissue cell types and physiological condition and acts through the signal transduction pathways mediated primarily by estrogen receptors. This study examined the effects of fulvestrant (Ful), a well-known antagonist for the estrogen receptor, on the action of $17{\beta}$-estradiol (E2) with respect to the proliferation and apoptosis of Chinese hamster ovarian (CHO) cells. We used different concentrations of E2, Ful, and E2 plus Ful during different treatment durations. Treatment with 15-40 ${\mu}M$ E2 significantly inhibited proliferation in a time-dependent manner, although it had no influence in concentrations up to 1 ${\mu}M$. Interestingly, Ful at 10-40 ${\mu}M$ also inhibited cellular proliferation in both a concentration- and time-dependent manner. In addition, Ful enhanced rather than decreased the inhibitory effect on cellular proliferation by E2 in combined treatment for 10 days. Thus, Ful does not appear to have an antagonistic effect on estrogen's anti-proliferative action in CHO cells. In TUNEL assays to confirm DNA fragmentation by E2 and/or Ful, CHO cells treated with 20 ${\mu}M$ E2 showed a TUNEL-positive reaction in most DAPI-stained nuclei, and cells treated with either 40 ${\mu}M$ Ful or 40 ${\mu}M$ Ful plus 20 ${\mu}M$ E2 also exhibited a TUNEL-positive reaction but at a lower rate compared to the E2-treated cells. These results indicate that Ful does not have an antagonistic effect on estrogen's anti-proliferative action in CHO cells, suggesting that the anti-proliferative and apoptosis-related mechanism(s) through DNA fragmentation by E2 and Ful may be mediated by different signal transduction pathways.
Keywords
$17{\beta}$-estradiol (E2); Chinese hamster ovarian (CHO); DNA fragmentation; fulvestrant; proliferation;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Hall, J. M., Couse, J. F. and Korach, K. S. 2001. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 276, 36869-36872.   DOI   ScienceOn
2 Hempling, R. E., Wong, C., Piver, M. S., Natarajan, N. and Mettlin, C. J. 1997. Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control study. Obstet Gynecol 89, 1012-1016.   DOI
3 Howell, A. 2006. Fulvestrant ('Faslodex'): current and future role in breast cancer management. Crit Rev Oncol Hematol 57, 265-273.   DOI
4 Min, G. S. 2011. Inhibitory effects of high concentrations of estrogen, progesterone and tamoxifen on proliferation of HeLa in culture. J Life Sci 21, 1746-1751   과학기술학회마을   DOI
5 Nelson, L. R. and Bulun, S. E. 2001. Estrogen production and action. J Am Acad Dermatol 45, S116-124.   DOI
6 Osborne, C. K., Wakeling, A. and Nicholson, R. I. 2004. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer 90, S2-6.   DOI
7 Chen, G. G., Zeng, Q. and Tse, G. M. 2008. Estrogen and its receptors in cancer. Med Res Rev 28, 954-974.   DOI   ScienceOn
8 Purdie, D., Green, A., Bain, C., Siskind, V., Ward, B., Hacker, N., Quinn, M., Wright, G., Russell, P. and Susil, B. 1995. Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. Survey of Women's Health Study Group. Int J Cancer 62, 678-684.   DOI   ScienceOn
9 Auersperg, N., Wong, A. S., Choi, K. C., Kang, S. K. and Leung, P. C. 2001. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22, 255-288.
10 Bai, W., Oliveros-Saunders, B., Wang, Q., Acevedo-Duncan, M. E. and Nicosia, S. V. 2000. Estrogen stimulation of ovarian surface epithelial cell proliferation. In Vitro Cell Dev Biol Anim 36, 657-666.   DOI
11 Choi, K. C., Kang, S. K., Tai, C. J., Auersperg, N. and Leung, P. C. 2001. Estradiol up-regulates antiapoptotic Bcl-2 messenger ribonucleic acid and protein in tumorigenic ovarian surface epithelium cells. Endocrinol 142, 2351-2360.   DOI
12 Cui, J., Shen, Y. and Li, R. 2013. Estrogen synthesis and signaling pathways during aging: from periphery to brain. Trends Mol Med 19, 197-209.   DOI
13 Cunat, S., Hoffmann, P. and Pujol, P. 2004. Estrogens and epithelial ovarian cancer. Gynecol Oncol 94, 25-32.   DOI
14 Song, R. X., Mor, G., Naftolin, F., McPherson, R. A., Song, J., Zhang, Z., Yue, W., Wang, J. and Santen, R. J. 2001. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst 93, 1714-1723.   DOI   ScienceOn
15 Robertson, C. N., Roberson, K. M., Padilla, G. M., O'Brien, E. T., Cook, J. M., Kim, C. S. and Fine, R. L. 1996. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst 88, 908-917.   DOI   ScienceOn
16 Tora, L., White, J., Brou, C., Tasset, D., Webster, N., Scheer, E. and Chambon, P. 1989. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 59, 477-487.   DOI   ScienceOn
17 Wardell, S. E., Marks, J. R. and McDonnell, D. P. 2011. The turnover of estrogen receptor $\alpha$ by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy. Biochem Pharmacol 82, 122-130.   DOI
18 Rao, M. C., Midgley, A. R. Jr. and Richards, J. S. 1978. Hormonal regulation of ovarian cellular proliferation. Cell 14, 71-78.   DOI   ScienceOn
19 Lewis, J. S., Meeke, K., Osipo, C., Ross, E. A., Kidawi, N., Li, T., Bell, E., Chandel, N. S. and Jordan, V. C. 2005. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst 97, 1746-1759.   DOI   ScienceOn
20 Li, Z. B., Chen, Y. X., Zhao, J. Y. and Lu, J. 2006. Effects of pharmacological concentrations of estrogens on growth of 3AO human ovarian cancer cells. Yi Chuan Xue Bao 33, 782-792.
21 McKenna, N. J., Lanz, R. B. and O'Malley, B. W. 1999. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 20, 321-344.
22 Yoo, C., Kim, S. B., Ahn, J. H., Jung, K. H., Ahn, Y., Gong, G., Kim, H. H., Kim, H. J., Son, B. H. and Ahn, S. H. 2011. Efficacy of fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer: a preliminary report. J Breast Cancer 14, 135-139.   DOI
23 Weiss, N. S., Lyon, J. L., Krishnamurthy, S., Dietert, S. E., Liff, J. M. and Daling, J. R. 1982. Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst 68, 95-98.
24 Wright, J. W., Stouffer, R. L. and Rodland, K. D. 2005. High-dose estrogen and clinical selective estrogen receptor modulators induce growth arrest, p21, and p53 in primate ovarian surface epithelial cells. J Clin Endocrinol Metab 90, 3688-3695.   DOI   ScienceOn
25 Yeh, W. L., Shioda, K., Coser, K. R., Rivizzigno, D., McSweeney, K. R. and Shioda, T. 2013. Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor ${\alpha}$ protein in MCF-7 cells require the CSK c-Src tyrosine kinase. PLoS One 8, e60889.   DOI
26 Robertson, J. F. 2007. Fulvestrant (Faslodex) - how to make a good drug better. Oncologist 12, 774-784.   DOI   ScienceOn
27 Saintier, D., Khanine, V., Uzan, B., Ea, H. K., de Vernejoul, M. C. and Cohen-Solal, M. E. 2006. Estradiol inhibits adhesion and promotes apoptosis in murine osteoclasts in vitro. J Steroid Biochem Mol Biol 99, 165-173.   DOI
28 Seli, E., Guzeloglu-Kayisli, O., Cakmak, H., Kayisli, U. A., Selam, B. and Arici, A. 2006. Estradiol increases apoptosis in human coronary artery endothelial cells by up-regulating Fas and Fas ligand expression. J Clin Endocrinol Metab 91, 4995-5001.   DOI
29 Lee, Y., Renaud, R. A., Friedrich, T. C. and Gorski, J. 1998. Estrogen causes cell death of estrogen receptor stably transfected cells via apoptosis. J Steroid Biochem Mol Biol 67, 327-332.   DOI
30 Purdie, D. M., Bain, C. J., Siskind, V., Russell, P., Hacker, N. F., Ward, B. G., Quinn, M. A. and Green, A. C. 1999. Hormone replacement therapy and risk of epithelial ovarian cancer. Br J Cancer 81, 559-563.   DOI   ScienceOn
31 Yaffe, K., Sawaya, G., Lieberburg, I. and Grady, D. 1998. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 279, 688-695.   DOI   ScienceOn